Research programme: zinc finger protein-based therapeutics - Sangamo/LifeScan

Drug Profile

Research programme: zinc finger protein-based therapeutics - Sangamo/LifeScan

Alternative Names: ZFN-based therapeutics - Sangamo Therapeutics/LifeScan

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Sangamo BioSciences
  • Class Cell therapies; Gene therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Genetic transcription modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 07 Apr 2008 This research programme is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top